# Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

> **NCT06521866** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 208 (estimated)

## Conditions studied

- Advanced Colorectal Carcinoma
- Immunotherapy

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Chemotherapy
- **RADIATION:** SABR
- **DRUG:** Targeted therapy

## Key facts

- **NCT ID:** NCT06521866
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06521866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06521866, "Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06521866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*